Raita Heiskanen

Serotype chimeric oncolytic adenovirus coding for GM‐CSF for treatment of sarcoma in rodents and humans

A. Hemminki, Simona Bramante, L. Vassilev, 2014, International journal of cancer.

Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus

K. Partanen, A. Hemminki, S. Tähtinen, 2013, Clinical Cancer Research.

Fc-gamma receptor polymorphisms as predictive and prognostic factors in patients receiving oncolytic adenovirus treatment

A. Hemminki, M. Hirvinen, V. Cerullo, 2013, Journal of Translational Medicine.

Predictive and Prognostic Clinical Variables in Cancer Patients Treated With Adenoviral Oncolytic Immunotherapy.

K. Hemminki, A. Hemminki, A. Kanerva, 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

Phase I study with ONCOS-102 for the treatment of solid tumors – an evaluation of clinical response and exploratory analyses of immune markers

J. Karbach, K. Partanen, N. Linder, 2016, Journal of Immunotherapy for Cancer.

Treatment of melanoma with a serotype 5/3 chimeric oncolytic adenovirus coding for GM‐CSF: Results in vitro, in rodents and in humans

D. Nettelbeck, A. Hemminki, Simona Bramante, 2015, International journal of cancer.

Oncolytic virotherapy for treatment of breast cancer, including triple-negative breast cancer

A. Hemminki, M. Siurala, Simona Bramante, 2016, Oncoimmunology.

Fc-gamma receptor polymorphisms as predictive and prognostic factors in patients receiving oncolytic adenovirus treatment

A. Hemminki, V. Cerullo, A. Kanerva, 2013, Journal of Translational Medicine.